Yasmine Wasfi - 20 Oct 2025 Form 4 Insider Report for Savara Inc (SVRA)

Role
Chief Medical Officer
Signature
/s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi
Issuer symbol
SVRA
Transactions as of
20 Oct 2025
Net transactions value
$0
Form type
4
Filing time
22 Oct 2025, 20:47:47 UTC
Previous filing
22 Oct 2025
Next filing
04 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wasfi Yasmine Chief Medical Officer ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE /s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi 22 Oct 2025 0002092127

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SVRA Common Stock Award $0 +35,000 +23% $0.000000 190,000 20 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SVRA Stock Option (Right to Buy) Award $0 +70,000 $0.000000 70,000 20 Oct 2025 Common Stock 70,000 $4.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") that vest in full on October 17, 2027, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2 The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of October 17, 2025, subject to the reporting person's continued service with the Issuer.